Gynecological Oncology Society of Chinese Medical Association. Clinical Practice Guidelines on Platinum Therapy in Gynecological Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(6): 881-901. DOI: 10.12290/xhyxzz.2021-0690
Citation: Gynecological Oncology Society of Chinese Medical Association. Clinical Practice Guidelines on Platinum Therapy in Gynecological Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(6): 881-901. DOI: 10.12290/xhyxzz.2021-0690

Clinical Practice Guidelines on Platinum Therapy in Gynecological Tumors

  • Platinum drugs have a wide spectrum of activity and remarkable therapeutic effects. Platinum-based chemotherapy is a widely recommended regimen for gynecology oncology. Carboplatin/paclitaxel is the "standard" combination of the first choice of therapy for patients with ovarian cancer. Cisplatin is preferred for cervical cancer. Preventing and mitigating adverse events and drug reactions are an important part of platinum treatment. For platinum-resistant disease, non-platinum-based agents or regimens are preferred. Platinum resistance remains an urgent challenge for the treatment of gynecological tumors. In order to standardize the clinical management of platinum therapy, we organized experts and scholars to discuss many times, and finally formed this consensus.
  • loading

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return